In the phase 3 OCEANIC-STROKE trial involving patients with noncardioembolic ischemic stroke or high-risk TIA, asundexian added to antiplatelet therapy led to a lower risk of ischemic stroke without increasing major bleeding. Full trial results: https://t.co/UPJGedYXFe
Editorial: Asundexian for Noncardioembolic Ischemic Stroke https://t.co/V1dVNbx4T8
Managing recurrent VTE despite anticoagulation in patients with cancer is tough ⚠️
This “How I Treat” review highlights practical strategies (confirm recurrence 🔍, assess adherence/interactions 💊, LMWH escalation or switch 📈) - More data needed! 📊
https://t.co/Asevq0atLk
@BloodPortfolio
In untreated chronic lymphocytic leukemia, fixed-duration venetoclax-based regimens were noninferior to continuous ibrutinib with regard to 3-year progression-free survival and were associated with higher MRD-negative rates. Full phase 3 CLL17 trial results and Research Summary: https://t.co/EQfrJ06UXj
If you attended #ISTH2025, you may have had the chance to hear about the COBRRA trial during our late-breaking research session! COBRRA is the FIRST head to head trial of apixaban vs rivaroxaban in the management of acute VTE.
Read the article here: https://t.co/9Kf4rApXLA
In an international, randomized trial involving patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period.
Full COBRRA trial results: https://t.co/tvPYrBCWj8
The @ISTH#SSC Subcom. on Platelets in Health & Disease is conducting a project to identify crit. patterns & mgmt strat. that may inform future care GLs for adult Glanzmann Thrombasthenia (GT) patients w/art. thromb. events.
Learn more & particiate at: https://t.co/K2PWoa8IBi
Mercredi 11 septembre au #CFH2024 c'est la Masterclass Thromboprophylaxie périopératoire avec Stéphanie Roullet et Thomas Quemeneur! @SFTHemostase#hemostase
Mercredi 11 septembre au #CFH2024 c'est la masterclass Modèles d'étude de l'hémostase et de la thrombose en flux avec Benoit Ho-Tin-Noé et Pierre Mangin! @SFTHemostase#hemostase#thrombose
Esteemed colleague and leader in the field of hemostasis, Pr Nigel Key will be our guest of honor for the 2024 congress of the French Society of Hemostasis and Thrombosis @SFTH#CFH2024 @cfh_2024
We are very much looking forward to his keynote lecture on tranexamic acid
📣 Le #CFH2024 c'est dans 2 semaines!
On n'oublie pas de s'inscrire
👉https://t.co/2KJ24AV2Xi
Petits conseils pour la valise : on pense au ☂ et 👟 adaptées en prévision d'une éventuelle drache 🌧
Le vendredi 13 septembre au #CFH2024 c’est l’occasion d’écouter Yacine Boulaftali expliquer le rôle des plaquettes dans l’hémorragie cérébrale et dans la formation et la rupture des anévrismes. On aurait tord de rater cette session ! @SFTHemostase@la_SFNV#hemostase#plaquettes